This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.
A new survey to mark Dementia Action Week (15-21 May) by Alzheimer’s Society reveals staggering statistics surrounding the confusion of symptoms of dementia and old age. ... Kate Lee, chief executive officer of Alzheimer’s Society, said the charity
Donanemab slowed the progression of early Alzheimer’s disease by 35% compared to placebo. ... Eli Lilly’s experimental Alzheimer’s drug, donanemab, has been shown to significantly slow cognitive and functional decline in patients with early-stage
Biogen and Eisai’s Alzheimer’s disease (AD) drug has been predicted to have a positive effect on long-term health outcomes, according to a new article published by Eisai in ... This decision was based on phase 2 data showing that Leqembi reduced the
Its experimental Alzheimer’s drug, donanemab, was rejected for accelerated approval by the US Food and Drug Administration in January this year due to the company not submitting enough trial data ... Lilly entered into a partnership with Roche last
to accelerate the ecosystem to aid in a timely and accurate diagnosis of Alzheimer’s.". ... The partnership comes just two months after Eisai and Biogen’s Alzheimer’s drug Leqembi (lecanemab-irmb) received accelerated approval in the US for
A new report from the Alzheimer’s Association has highlighted a need to improve patient-physician communication surrounding cognitive concerns. ... monitor disease progression and treat when appropriate,” said Maria Carrillo, chief science officer,
More from news
Approximately 194 fully matching, plus 429 partially matching documents found.
A look through the calendar for the next few months shows delegates coming together for conditions ranging from Alzheimer’s through to cardiology and urology, and journeying from Amsterdam to Vancouver ... From a pharma company’s perspective, a well-
It stops time and halts joy because of troublesome dyskinesia. This is Parkinson’s disease. ... Alzheimer’s disease, schizophrenia and other neurological and psychiatric disorders.
By Charlotte Maule. With the potential approval of the first disease-modifying treatment (DMT) for Alzheimer’s disease (AD) on the horizon – and further treatment candidates in development – stakeholders need to ... Organization. Diagnosis of
Dr Susan Mitchell, head of policy at Alzheimer’s Research UK, said: “Addressing health inequalities is a key part of the challenge of tackling dementia. ... the impact of higher levels of the p-tau181, a protein strongly associated with markers of
Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... other than the build-up of the hallmark Alzheimer’s proteins, amyloid and tau.
More from intelligence
Approximately 9 fully matching, plus 46 partially matching documents found.
Speaking on his appointment, Mole said: “It’s great to join Hanover Communications. ... With fifteen years’ experience of working with government, parliament and healthcare charities – including Cancer Research UK, Diabetes UK and the Alzheimer's
She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science
The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.
Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.
More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.
Common signs of Alzheimer's disease include difficulties with:. Remembering recent conversations or events. ... It is the second most common type of dementia after Alzheimer's disease.
The RISE study includes a research registry created to help ensure the LGBTQIA+ community is represented in Alzheimer’s research.
Alzheimer’s disease). ... One of IRDiRC’s goals is to stimulate the development and approval of 1, 000 new therapies for rare diseases by 2027.
A glimmer of hope for Alzheimer’s patients, but at what cost? ... Alzheimer’s disease.
Caring for people with dementia on hospital wards. London: Alzheimer's Society; 2009. ... Dementia UK: report to the Alzheimer’s society. London: Alzheimer’s Society; 2014.
More from PMHub
Approximately 3 fully matching, plus 27 partially matching documents found.
No results were found
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...